Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-06-12 Director's Dealing
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-06-12 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 10, 2025, reporting the results of the 2025 Annual Meeting of Stockholders of vTv Therapeutics Inc. It details the voting results for the election of directors and the ratification of the independent auditor. The key section is 'Item 5.07 Submission of Matters to a Vote of Security Holders,' which explicitly provides official voting results from the shareholder meeting. The document is relatively short (3945 characters) and focuses solely on voting outcomes rather than presenting a full report or financial data. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-06-12 English
FORM 4
Director's Dealing
2025-05-22 English
FORM 3
Director's Dealing
2025-05-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the appointment of a new executive vice president and chief financial officer, Michael Tung, including details about his employment agreement and compensation. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It is specifically about management changes, which corresponds to the Board/Management Information category (MANG). The document length and content confirm it is not a brief announcement or a certification but a substantive filing about management changes.
2025-05-19 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 16, 2025. It specifically mentions that the company posted an investor presentation on its website, which is attached as Exhibit 99.1. The text states that the presentation will be used in meetings with investors and analysts and may be updated. The document itself is short (3760 characters) and primarily serves to announce the availability of the investor presentation rather than containing the full presentation or detailed financial data. According to the rules, such a document is best classified as an Investor Presentation (IP) because it is a detailed presentation for investors focusing on financials, strategy, and market position, and it is attached as an exhibit to the filing. The document is not a full financial report, nor is it merely an announcement of a report publication. Therefore, the classification is IP with high confidence.
2025-05-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.